BY IDA JORGENSEN
-
Compounder warned by FDA after multiple breaches
FDA points warning to Prorx Pharmacy Community after inspection of drug manufacturing. The company found issues with mislabeling, sterility and lack of understanding about negative…
-
EU prepares economic “bazooka” in response to Trump: Could hit US pharma companies
Nonetheless, EU’s action to Trump’s toll risks versus Denmark will certainly not at first be targeted at United States pharma business’ accessibility to the Europ…
-
Analysts: New data pushes Novo’s cagrisema into the background
Friday’s encouraging stage 1b/2a results for amycretin persuaded numerous experts that Novo Nordisk will certainly concentrate on the brand-new weight-loss prospect over cagr…
-
Four biotech companies line up for IPO – fund director hopes for possible “ketchup effect”
If 4 IPO prospects succeed in the aftermarket, it can cause much more biotech IPOs in 2025, according to a fund supervisor.
-
A broken market and political consequences – upcoming US price negotiations challenge Trump
Trump is anticipated to distance himself from Joe Biden’s regulation on straight rate arrangements in between the United States federal government and medication suppliers. H…
-
Coave Therapeutics secures EUR 32m in investment round led by Novo Holdings
Novo Holdings, along with financial investment financial institution Bpifrance, led the Collection A funding of French biotech business Coave Therapies.
-
Drug manufacturers got through US price negotiations without decisive losses
The statement of the following 15 medications to be consisted of in cost settlements impends– with Novo Nordisk’s Ozempic anticipated to land in the swimming pool.
